News Takeda gets return on Ariad buy with approval of brigatinib But Japanese pharma bracing for US patent expiry on blockbuster Velcade
News J&J's Remicade faces further biosimilar competition in US FDA approves Samsung Bioepis biosimilar.
News Doubts over AbbVie PARP inhibitor after double trial failure Veliparib fails in two phase 3 trials.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News UK biotech Astex celebrates as Novartis breast cancer drug a... Cambridge firm played key role in discovery of potential blockbuster Kisqali.
News Servier and Pfizer begin trials for off-the-shelf T-cell can... Companies hope to challenge traiblazers Novartis and Kite.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.